NCT02572752View on ClinicalTrials.gov

Relative Bioavailability of 2 Oral Formulations of Nintedanib

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Healthy
Interventions
DRUG

Nintedanib

1 soft gelatine capsule, single dose, oral

DRUG

Nintedanib

Nintedanib, 2 soft gelatine capsules, single dose, oral

DRUG

Nintedanib

Trial Locations (1)

Unknown

Boehringer Ingelheim Investigational Site, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY